Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Buy” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has earned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $19.14.

A number of equities research analysts have recently weighed in on REPL shares. Jefferies Financial Group boosted their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, HC Wainwright increased their target price on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday.

Replimune Group Trading Down 1.2 %

NASDAQ REPL opened at $13.59 on Friday. The company’s fifty day moving average price is $12.28 and its two-hundred day moving average price is $11.35. The company has a market capitalization of $929.79 million, a price-to-earnings ratio of -4.46 and a beta of 1.28. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, research analysts predict that Replimune Group will post -2.88 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. SG Americas Securities LLC grew its position in Replimune Group by 14.7% in the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after buying an additional 3,374 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Replimune Group by 3.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock valued at $2,733,000 after buying an additional 8,074 shares during the period. Barclays PLC raised its position in shares of Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after acquiring an additional 217,308 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.